The named-buyer map.
First cut, built overnight.

Ed, this is the working document for Wednesday. One pass through one of our data sources, run after Monday's conversation, so we can argue about something real instead of a concept. Every number below is from that single pass, before curation and before verification.

Working session document, no pricing

1,328

Access-titled individuals found in the first pass

Organizations they sit in

422

At director level or above

Title families that matter to AccessSync One

Base: the first 500 pharmaceutical and biopharmaceutical organizations in one source, US only, titles matching market access, patient access, field reimbursement, patient services and HEOR. This is one source of several, and the sweep deliberately stopped early.

The shape of the market

Five title families, one buying conversation.

Your number from Monday was about 2,000 named individuals. One pass through one source found 1,328 before we tried hard. The full mapping runs every source we hold, strips the noise, and verifies each person. Your 2,000 is not an estimate we have to take on faith. It is a floor we can prove.

Title family	Found in first pass	Why they matter to the AccessSync sale
Market Access	386	The core buyer. Owns access strategy and the tools the field executes with.
Patient Services	322	Owns hub and support programs where coverage clarity decides patient starts.
Patient Access	251	The second title you named Monday. Often the same conversation, different door.
Reimbursement	246	Field reimbursement leads live daily in the questions AccessSync One answers.
HEOR	123	Influencers and evidence owners who shape the access argument internally.

Their titles rarely carry the brand they cover. Mapping each person to their therapy is research work, and it is exactly the work the engine does before anyone is contacted.

Named, not notional

Ten rows from the first pass.

Ten real people across ten pharmaceutical manufacturers, exactly as the first pass returned them. Tell us which rows look right and which look off. That correction is the working session.

Name	Title, as found	Organization	State	Profile
Paula Davis	Director, Field Reimbursement and Health Care Economics Services	Abbott	MN	LinkedIn
Juan Roman	Senior Director, Global Market Access, Specialty	AbbVie	IL	LinkedIn
Tracey Walsh	Director, Patient Access Services	Alkermes	MA	LinkedIn
Chelsea Glinski	Executive Director, Market Access and Reimbursement Strategy	Astellas	IL	LinkedIn
Jennifer Pocoski	Deputy Director, Global HEOR / Global Market Access	Bayer	NY	LinkedIn
Christine Marsh	Vice President, Market Access	Boehringer Ingelheim	NY	LinkedIn
Scott Rubin	Director, Market Access, Oncology Business Unit	Eli Lilly	IN	LinkedIn
Sal Grausso	Vice President, Patient Access	Endo	PA	LinkedIn
Cristian Azcarate	Associate Director, Field Reimbursement Management Operations	Genentech	CA	LinkedIn
Nancy Moody	Director, Market Access and Business Intelligence	Grifols	NC	LinkedIn

Honest label: these rows are a pre-verification snapshot. Some of these people will have changed title or company since the source captured them, and the raw pass also pulls in hospital-side patient access roles that are the wrong world entirely. That is not a flaw in the plan. It is the point of it: every person is re-verified live, person by person, employer by employer, before anyone is ever contacted. A list nobody has cleaned is exactly what the engine exists to fix.

What the full map adds from here: every source we hold cross-checked, the provider-side noise stripped out, each person tied to their brand and therapy, and the launch-team route layered on top, the teams built 12 to 18 months before a therapy reaches approval.

The second gap from Monday

The seat we would place.

The engine solves the reach problem. This seat solves the calendar problem. The profile below is the specification we would recruit against, sourced through our senior network in US healthcare rather than a job board.

Knows the room

Ten-plus years selling data, software or services into US pharma commercial teams. Speaks market access fluently: payers, coverage, pull-through, the field's daily reality. No ramp spent learning the vocabulary.

Sourced, not advertised

Recruited through our senior network in the sector, people with decades of working relationships across US medical and pharma. A shortlist you interview, not a stack of resumes to sift.

Ramped by the engine

They never start from a cold desk. The engine hands them researched, warm conversations from the first weeks, and we train them on AccessSync One, your pitch and your market.

Yours at the end

Embedded in your business through the engagement, working your pipeline day to day, transitioned to you at handover. You end with a working seller and the machine that feeds them.

A first sales hire made blind is the most expensive guess a small company makes. This removes the guess: the pipeline exists before the seat does, and the seat arrives with the sector already in their pocket.

Wednesday's working session

Three things we want your read on.

The map: which title families actually sign, which only influence, and which organizations on the sample look right or wrong to you.

The seat: the seniority you would want in the room, and what the first ninety days should look like from your side.

The route past the 2,000: whether the launch-team angle matches what you see in the market, and which other doors are worth opening.

Nothing here is final. That is deliberate. The fastest way to a right plan is to put a wrong one in front of the person who knows the market best.

The named-buyer map.First cut, built overnight.